NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
Express News | NRx Pharmaceuticals Has Obtained Up To Approximately $16M In Convertible Debt Financing From An Institutional Investor To Support The 2024 New Drug Application Filing Its Two Lead Products, NRX-100 And NRX-101 And To Retire Existing Debt From...
Express News | NRX Pharmaceuticals - Intends to Use Net Proceeds From Financing to Support Nda Filing of NRX-100 and NRX-101
Express News | NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces up to $16 Million Senior Secured Debt Financing From Anson Funds
HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)
NRX Pharmaceuticals Analyst Ratings
Express News | NRX Pharmaceuticals Inc: Remains on Track to File Nda for NRX-100 in Q4 2024 With Anticipated Pdufa Date in Q2 2025
Express News | Hope Therapeutics, Inc. and NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announce Alignment With FDA on Pediatric Study Plan for NRX-100 (Ketamine)
Express News | NRX Pharmaceuticals Inc - Petition to Prevent NRX Share Sales Denied by Utah Arbitrator
Express News | NRX Pharmaceuticals Inc - to Proceed With Spinoff of Hope Therapeutics
Express News | Hope Therapeutics, Inc. and NRX Pharmaceuticals (Nasdaq:Nrxp) Announce Arbitration Order Enabling Hope Therapeutics Spinoff
Express News | NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sales Of NRX-100 (IV Ketamine) Pending FDA Approval,...
Press Release: NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
Express News | NRX Pharmaceuticals Inc: Nda for NRX-100 in Advanced Preparation for Submission in 2024, Potential Revenue in 2025
Express News | NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
Express News | NRX Pharmaceuticals Inc - Agreement Provided for the Joint Development, Supply, Marketing, Commercialization and License to Alvogen of NRX-101
Express News | NRX Pharmaceuticals Inc - Continues to Finalize a New Drug Approval Application for Intravenous Ketamine (NRX-100), to Be Submitted This Year
Express News | NRX Pharmaceuticals- Under Deal, Co, Alvogen Will, Discuss, Negotiate and Seek to Agree to a Royalty Amount Due Alvogen by the Company Within 30 Days
Express News | NRX Pharmaceuticals- Got Notice of Termination of Exclusive, Global – Development, Supply, Marketing & License Agreement, by & Between Co, Alvogen
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024